Abstract
ObjectiveThe protein GS28 (28-kDa Golgi SNARE protein) has been described as a SNARE (Soluble N-ethylmaleimide-sensitive factor attachment protein receptors) protein family member that plays a critical role in mammalian ER-Golgi or intra-Golgi vesicle transport. Little is known about the possible roles of GS28 in pathological conditions. The purpose of this study was to evaluate GS28 expression in cervical cancer tissues and explore its correlation with clinicopathological features and prognosis.MethodsWe investigated GS28 expression in 177 cervical cancer tissues by using immunohistochemistry and evaluated the correlation of GS28 expression with clinicopathological features, the expression of p53 and Bcl-2, and prognosis of cervical cancer patients. Immunoblotting was performed using six freshly frozen cervical cancer tissues to confirm the subcellular localization of GS28.ResultsImmunoreactivity of GS28 was observed in both nuclear and cytoplasmic compartments of cervical cancer cells. High nuclear expression of GS28 was associated with advanced tumor stages (P = 0.036) and negative expression of p53 (P = 0.036). In multivariate analyses, patients with high nuclear expression of GS28 showed significantly worse overall survival (OS) (hazard ratio = 3.785, P = 0.003) and progression-free survival (PFS) (hazard ratio = 3.019, P = 0.008), compared to those with low or no nuclear expression. It was also a reliable, independent prognostic marker in subgroups of patients with early stage T1 and negative lymph node metastasis in OS (P = 0.008 and 0.019, respectively). The nuclear expression of GS28 was confirmed by immunoblotting.ConclusionHigh nuclear expression of GS28 is associated with poor prognosis in early-stage cervical cancer patients. GS28 might be a novel prognostic marker and a potential therapeutic target in cervical cancer treatment.
Highlights
Cervical cancer is the third most prevalent malignancy and the fourth leading cause of cancer deaths among women worldwide, despite the successful Papanicolaou smear based screening and treatment program [1]
High nuclear expression of GS28 was associated with advanced tumor stages (P = 0.036) and negative expression of p53 (P = 0.036)
High nuclear expression of GS28 is associated with poor prognosis in early-stage cervical cancer patients
Summary
Cervical cancer is the third most prevalent malignancy and the fourth leading cause of cancer deaths among women worldwide, despite the successful Papanicolaou smear based screening and treatment program [1]. Patients with early-stage cervical cancer have good prognoses with five-year survival rates of 90–95%, a significant number of patients die due to relapses [2]. Cisplatin is commonly used for the treatment of cervical cancer; drug resistance is common and serious side effects may develop [3]. More effective and safe approaches are required to tackle the survival of some cancer cells that cause the failure of treatment. The identification of biomarkers to predict the potential progression of cancer and prognosis of patients with cervical cancer is desirable for planning appropriate individualized therapies
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
